CERo Therapeutics Merges With Phoenix Biotech Acquisition Corp.
Cooley advised CERo Therapeutics, an immunotherapy company, on its merger agreement with Phoenix Biotech Acquisition Corp. CERo Therapeutics Merges With Phoenix Biotech Acquisition Corp.
Cooley Advises on MindMed’s Successful Proxy Contest
Cooley advised Mind Medicine (MindMed), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, on its successful proxy contest against FCM MM Holdings. Cooley Advises on MindMed’s Successful Proxy Contest
Snyk Acquires Enso Security
Cooley advised Snyk, a leader in developer security, on its acquisition of Enso Security, pioneers of the industry’s first application security posture management (ASPM) solution. Snyk Acquires Enso Security
Veritone Acquires Broadbean
Cooley is advising Veritone, an artificial intelligence company, on its acquisition of Broadbean for $52 million. Lawyers Bram Couvreur, Natalie Vernon and Rajdeep Bains are leading the Cooley team advising Veritone. Veritone Acquires Broadbean
VectivBio to be Acquired by Ironwood
Cooley advised VectivBio, a clinical-stage biotech company focused on the discovery and development of treatments for severe, rare gastrointestinal (GI) conditions, on its acquisition by Ironwood, with an estimated aggregate consideration of approximately $1 billion. VectivBio to be Acquired by Ironwood
Toluna Acquires MetrixLab
Cooley advised Toluna, a global insights technology and panel provider, in its acquisition of MetrixLab, a market research and insights leader from Macromill. Toluna Acquires MetrixLab
Absolute Software Announces $870 Million Acquisition by Crosspoint Capital
Cooley advised Absolute Software, a data risk management solutions and endpoint security provider, on its acquisition by Crosspoint Capital for approximately $870 million, inclusive of debt. Absolute Software Announces $870 Million Acquisition by Crosspoint Capital
Zion Pharma Announces Sale of Lead Program to Roche
Cooley advised Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, on the acquisition of its lead program, ZN-A-1041, by Roche. Partners Lila Hope and Yiming Liu led the Cooley team. Zion Pharma Announces Sale of Lead Program to Roche
NKGen Biotech Announces Merger With Graf Acquisition Corp. IV
Cooley advised NKGen Biotech, a clinical-stage biotechnology company, on its business combination agreement with special purpose acquisition company Graf Acquisition Corp. IV – a combination that will result in NKGen becoming a publicly listed company. NKGen Biotech Announces Merger With Graf Acquisition Corp. IV
Bitdeer Announces Merger With Blue Safari
Cooley advised Bitdeer Technologies Holding Company, a world-leading technology company for the cryptocurrency mining community, on its business combination with Blue Safari Group Acquisition Corp., a special purpose acquisition company. Bitdeer Announces Merger With Blue Safari